title: Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.
abstract: OBJECTIVE
  Administration of atypical antipsychotics often induces significant weight gain and metabolic changes. Little is known about subjective weight-related parameters in adolescent patients. Therefore, this cross-sectional, explorative study aimed to assess these parameters and their relationship with biological weight-related parameters.
  
  
  METHODS
  74 patients (mean age: 19.9 [SD ± 2.3] years; 66.2% male) with schizophrenia under clozapine or olanzapine treatment were examined. Subjective well-being, eating behavior, body perception and social functioning were assessed, using the Three-Factor-Eating-Questionnaire, FKB-20 Body Perception Questionnaire, Subjective Well-being under Neuroleptics, Short Form and Global Assessment of Functioning. Patients' biological weight-related parameters were measured as well. Gender differences as well as associations between subjective and biological weight-related parameters were evaluated.
  
  
  RESULTS
  Female patients reported significantly worse negative body appraisal and physical functioning than males. An elevated BMI was associated with impaired physical functioning in females and with negative body appraisal and hunger in males.
  
  
  CONCLUSIONS
  In our sample of young patients with schizophrenia unter treatment with atypical antipsychotics, an elevated BMI was associated with impaired physical functioning and negative body appraisal, respectively. Bearing in mind the high risk of obesity in this population, the mentioned impairments should be accounted for, especially in terms of compliance and quality of life.
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie und -psychotherapie, Universitätsklinikum Gießen und Marburg gGmbH, Standort Marburg. christian.bachmann@charite.de
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Bachmann
authors.forename: Stefan
authors.initials: S
authors.lastname: Gebhardt
authors.forename: Dirk
authors.initials: D
authors.lastname: Lehr
authors.forename: Michael
authors.initials: M
authors.lastname: Haberhausen
authors.forename: Christoph
authors.initials: C
authors.lastname: Kaiser
authors.forename: Bärbel
authors.initials: B
authors.lastname: Otto
authors.forename: Frank M
authors.initials: FM
authors.lastname: Theisen
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D001828:Body Image; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D054439:Ghrelin / Q000097:blood; D006801:Humans; D006815:Hunger / Q000187:drug effects; D020738:Leptin / Q000097:blood; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000523:psychology; D000077152:Olanzapine; D010809:Physical Fitness; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012737:Sex Factors; D012917:Social Adjustment; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D054439:Ghrelin; D020738:Leptin; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine